Y Intercept Hong Kong Ltd Invests $742,000 in Immatics N.V. $IMTX

Y Intercept Hong Kong Ltd acquired a new stake in shares of Immatics N.V. (NASDAQ:IMTX) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 75,427 shares of the company’s stock, valued at approximately $742,000. Y Intercept Hong Kong Ltd owned about 0.06% of Immatics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in Immatics in the 4th quarter worth approximately $2,189,000. Baker BROS. Advisors LP raised its stake in Immatics by 18.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock valued at $103,042,000 after buying an additional 1,925,193 shares during the last quarter. Sofinnova Investments Inc. lifted its holdings in shares of Immatics by 54.2% during the 4th quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock valued at $36,073,000 after buying an additional 1,207,705 shares during the period. Monashee Investment Management LLC purchased a new position in shares of Immatics in the 4th quarter worth $1,684,000. Finally, Ishara Investments LP purchased a new position in shares of Immatics in the 4th quarter worth $840,000. Institutional investors own 64.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. TD Cowen began coverage on Immatics in a research report on Tuesday, April 28th. They set a “buy” rating for the company. Wall Street Zen lowered shares of Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings cut shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Jefferies Financial Group began coverage on shares of Immatics in a report on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of Immatics in a research report on Tuesday, May 19th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $20.80.

Immatics Price Performance

Shares of IMTX opened at $9.68 on Monday. Immatics N.V. has a 1 year low of $5.05 and a 1 year high of $12.41. The company has a 50 day simple moving average of $10.34 and a two-hundred day simple moving average of $10.17. The firm has a market cap of $1.30 billion, a P/E ratio of -4.86 and a beta of 1.32.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The company had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. On average, sell-side analysts anticipate that Immatics N.V. will post -1.67 earnings per share for the current year.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.